Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
1. FDA accepted GILD's NDA for lenacapavir, targeting HIV prevention. 2. Lenacapavir demonstrated 100% efficacy in Phase 3 trial results. 3. GILD stock rose 74% in the past year, trading below industry average. 4. Potential federal funding cuts for HIV prevention may impact GILD's market growth. 5. GILD needs to increase PrEP users to meet $4 billion sales target.